Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study - Moreau, Philippe; Pylypenko, Halyna; Grosicki, Sebastian; Karamanesht, Ievgenii; Leleu, Xavier; Grishunina, Maria; Rekhtman, Grigoriy; Masliak, Zvenyslava; Robak, Tadeusz; Shubina, Anna; Arnulf, Bertrand; Kropff, Martin; et al. (Lancet Oncology, 2011)